[{"address1": "2380 Conejo Spectrum Street", "address2": "Suite 200", "city": "Thousand Oaks", "state": "CA", "zip": "91320", "country": "United States", "phone": "805 623 4211", "website": "https://www.atarabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.", "fullTimeEmployees": 165, "companyOfficers": [{"maxAge": 1, "name": "Dr. Pascal  Touchon D.V.M.", "age": 60, "title": "President, CEO & Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 1044629, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Anhco  Nguyen Ph.D.", "age": 50, "title": "Executive VP and Chief Scientific & Technical Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 696342, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. K. Amar Murugan", "age": 47, "title": "Executive VP & Chief Legal Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 718504, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Hyllengren", "age": 47, "title": "Executive VP & Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Alex  Chapman", "title": "Vice President of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jill  Henrich", "age": 60, "title": "Executive VP and Global Head of Regulatory Affairs & Quality", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Maziasz", "title": "Executive VP & Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rajani  Dinavahi M.D.", "title": "Senior VP & Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.05, "open": 9.09, "dayLow": 9.09, "dayHigh": 10.69, "regularMarketPreviousClose": 9.05, "regularMarketOpen": 9.09, "regularMarketDayLow": 9.09, "regularMarketDayHigh": 10.69, "beta": 0.498, "forwardPE": -1.1402508, "volume": 474355, "regularMarketVolume": 474355, "averageVolume": 118789, "averageVolume10days": 269720, "averageDailyVolume10Day": 269720, "bid": 7.54, "ask": 10.16, "bidSize": 200, "askSize": 100, "marketCap": 49150500, "fiftyTwoWeekLow": 4.975, "fiftyTwoWeekHigh": 49.0, "priceToSalesTrailing12Months": 0.7878324, "fiftyDayAverage": 8.5986, "twoHundredDayAverage": 14.39485, "currency": "USD", "enterpriseValue": 61891192, "profitMargins": -2.90201, "floatShares": 3354570, "sharesOutstanding": 4915050, "sharesShort": 378453, "sharesShortPriorMonth": 539986, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.077, "heldPercentInsiders": 0.090179995, "heldPercentInstitutions": 0.58892, "shortRatio": 7.0, "shortPercentOfFloat": 0.078099996, "impliedSharesOutstanding": 4915050, "bookValue": -22.608, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -181048000, "trailingEps": -39.0, "forwardEps": -8.77, "lastSplitFactor": "1:25", "lastSplitDate": 1718841600, "enterpriseToRevenue": 0.992, "enterpriseToEbitda": -0.382, "52WeekChange": -0.7649351, "SandP52WeekChange": 0.24014747, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ATRA", "underlyingSymbol": "ATRA", "shortName": "Atara Biotherapeutics, Inc.", "longName": "Atara Biotherapeutics, Inc.", "firstTradeDateEpochUtc": 1413466200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2e7d1e9f-6492-3d1e-8dac-1008d2ea8165", "messageBoardId": "finmb_248196818", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.0, "targetHighPrice": 325.0, "targetLowPrice": 9.0, "targetMeanPrice": 90.5, "targetMedianPrice": 14.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 35292000, "totalCashPerShare": 7.18, "ebitda": -162124992, "totalDebt": 52702000, "quickRatio": 0.254, "currentRatio": 0.421, "totalRevenue": 62387000, "revenuePerShare": 12.263, "returnOnAssets": -0.57482, "freeCashflow": -2966750, "operatingCashflow": -142008992, "revenueGrowth": 28.927, "grossMargins": -2.01896, "ebitdaMargins": -2.5987, "operatingMargins": -0.62413, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]